Seizert Capital Partners LLC Has $49.59 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Seizert Capital Partners LLC trimmed its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 1.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 190,262 shares of the medical research company's stock after selling 2,580 shares during the period. Amgen accounts for about 2.2% of Seizert Capital Partners LLC's portfolio, making the stock its 13th biggest holding. Seizert Capital Partners LLC's holdings in Amgen were worth $49,590,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. SPC Financial Inc. grew its position in Amgen by 25.5% during the 4th quarter. SPC Financial Inc. now owns 3,354 shares of the medical research company's stock worth $874,000 after acquiring an additional 681 shares during the last quarter. Assetmark Inc. raised its stake in Amgen by 5.5% during the 4th quarter. Assetmark Inc. now owns 293,970 shares of the medical research company's stock worth $76,620,000 after buying an additional 15,399 shares during the period. Smithfield Trust Co increased its holdings in Amgen by 3.3% during the 4th quarter. Smithfield Trust Co now owns 3,788 shares of the medical research company's stock worth $977,000 after purchasing an additional 120 shares in the last quarter. Cypress Capital Group increased its holdings in Amgen by 0.9% during the 4th quarter. Cypress Capital Group now owns 13,647 shares of the medical research company's stock worth $3,557,000 after purchasing an additional 128 shares in the last quarter. Finally, Victory Capital Management Inc. increased its holdings in Amgen by 15.0% during the 4th quarter. Victory Capital Management Inc. now owns 824,291 shares of the medical research company's stock worth $214,843,000 after purchasing an additional 107,374 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP David M. Reese sold 8,711 shares of Amgen stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the completion of the transaction, the executive vice president now owns 62,147 shares of the company's stock, valued at $18,222,743.34. The trade was a 12.29 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the sale, the senior vice president now owns 7,210 shares of the company's stock, valued at approximately $2,195,228.70. This represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 69,341 shares of company stock worth $20,644,335 in the last 90 days. Company insiders own 0.69% of the company's stock.

Amgen Price Performance

NASDAQ AMGN traded up $4.38 during trading hours on Wednesday, hitting $316.57. 2,628,966 shares of the company's stock traded hands, compared to its average volume of 2,544,250. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The company has a market capitalization of $170.06 billion, a PE ratio of 41.93, a PEG ratio of 2.63 and a beta of 0.56. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The firm's 50-day moving average is $283.80 and its 200-day moving average is $299.78.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Equities analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.01%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio (DPR) is 126.09%.

Wall Street Analyst Weigh In

A number of analysts recently commented on AMGN shares. Piper Sandler Companies reaffirmed an "overweight" rating and set a $310.00 price target on shares of Amgen in a research report on Thursday, January 2nd. Truist Financial decreased their price target on Amgen from $333.00 to $298.00 and set a "hold" rating for the company in a research report on Wednesday, January 8th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $324.00 price target on shares of Amgen in a research report on Friday, January 24th. Leerink Partners decreased their target price on Amgen from $349.00 to $302.00 in a research report on Wednesday, November 27th. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $314.95.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.